MX2009010886A - Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa. - Google Patents

Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa.

Info

Publication number
MX2009010886A
MX2009010886A MX2009010886A MX2009010886A MX2009010886A MX 2009010886 A MX2009010886 A MX 2009010886A MX 2009010886 A MX2009010886 A MX 2009010886A MX 2009010886 A MX2009010886 A MX 2009010886A MX 2009010886 A MX2009010886 A MX 2009010886A
Authority
MX
Mexico
Prior art keywords
inhibitors
disorders
nase
phosphatidylinositol
pyrimidine derivatives
Prior art date
Application number
MX2009010886A
Other languages
English (en)
Inventor
Neil Anthony Pegg
Stephen Price
Edward Mcdonald
Stephen Joseph Shuttleworth
Paul John Goldsmith
Timothy Colin Hancox
Elsa Amandine Dechaux
Jonathan Martin Large
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0707088A external-priority patent/GB0707088D0/en
Priority claimed from GB0707611A external-priority patent/GB0707611D0/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2009010886A publication Critical patent/MX2009010886A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Dental Preparations (AREA)

Abstract

La invención proporciona compuestos que son pirimidinas de la fórmula (i): en donde R1, R2 son como se definen en la presente, y/o una sal farmacéuticamente aceptable de los mismos. Estos compuestos son inhibidores de PI3K y de esta manera se pueden usar para tratar enfermedades y trastornos que surgen del crecimiento, función o comportamiento celular anormal asociado con PI3-cinasa tal como cáncer, trastornos inmunitarios, enfermedad cardiovascular, infección viral, inflamación, trastornos de la función endócrina/metabolismo y trastornos neurológicos.
MX2009010886A 2007-04-12 2008-04-14 Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa. MX2009010886A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0707088A GB0707088D0 (en) 2007-04-12 2007-04-12 Pharmaceutical compounds
GB0707611A GB0707611D0 (en) 2007-04-19 2007-04-19 Pharmaceutical compounds
PCT/GB2008/001301 WO2008125839A2 (en) 2007-04-12 2008-04-14 Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase

Publications (1)

Publication Number Publication Date
MX2009010886A true MX2009010886A (es) 2009-12-14

Family

ID=39832798

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010886A MX2009010886A (es) 2007-04-12 2008-04-14 Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa.

Country Status (13)

Country Link
US (1) US20100130496A1 (es)
EP (1) EP2150546B1 (es)
JP (1) JP2010523639A (es)
KR (1) KR20100016433A (es)
CN (1) CN101765597A (es)
AT (1) ATE496045T1 (es)
AU (1) AU2008237721A1 (es)
BR (1) BRPI0810641A2 (es)
CA (1) CA2683624A1 (es)
DE (1) DE602008004650D1 (es)
IL (1) IL201365A0 (es)
MX (1) MX2009010886A (es)
WO (1) WO2008125839A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2146981A1 (en) * 2007-04-12 2010-01-27 F. Hoffmann-Roche AG Pharmaceutical compounds
CA2729045A1 (en) 2008-07-31 2010-02-04 Philippe Bergeron Pyrimidine compounds, compositions and methods of use
JP5555236B2 (ja) 2008-08-25 2014-07-23 アイアールエム・リミテッド・ライアビリティ・カンパニー ヘッジホッグ経路モジュレーター
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
JPWO2010092962A1 (ja) 2009-02-12 2012-08-16 アステラス製薬株式会社 へテロ環誘導体
EP2499143B1 (en) 2009-11-12 2016-03-16 F.Hoffmann-La Roche Ag N7-substituted purine and pyrazolopyrimidine compounds, compositions and methods of use
JP5579864B2 (ja) 2009-11-12 2014-08-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｎ−９−置換プリン化合物、組成物及び使用の方法
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2604601B1 (en) 2010-08-10 2016-02-24 Astellas Pharma Inc. Hetero ring compound
CN103189356B (zh) 2010-09-29 2015-11-25 英特维特国际股份有限公司 N-杂芳基化合物
TW201500358A (zh) 2010-12-16 2015-01-01 赫夫門羅氏藥廠股份有限公司 三環ｐｉ３ｋ抑制劑化合物及其使用方法
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2790705B1 (en) 2011-12-15 2017-12-06 Novartis AG Use of inhibitors of the activity or function of pi3k
AU2013241853B2 (en) 2012-03-28 2017-11-09 Intervet International B.V. Heteroaryl compounds with A-cyclic bridging unit
KR20160027219A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
US20150258127A1 (en) 2012-10-31 2015-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
WO2015071230A1 (en) * 2013-11-15 2015-05-21 Bayer Cropscience Ag Catalytic hydrogenation of nitriles
RU2713179C2 (ru) 2014-02-21 2020-02-04 Фрост Биолоджик, Инк. Антимитотические амиды для лечения рака и пролиферативных заболеваний
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
GB201602527D0 (en) * 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3558944B1 (en) 2016-12-21 2022-03-09 Bayer CropScience Aktiengesellschaft Hydrogenation of a substituted 2-methyl cyanopyridyl derivative in the presence of a raney cobalt catalyst
CN110914265B (zh) * 2017-05-15 2022-12-23 密歇根大学董事会 作为lsd-1抑制剂的吡咯并[2,3-c]吡啶和相关类似物
EP3676264A1 (en) * 2017-08-28 2020-07-08 Acurastem Inc. Pikfyve kinase inhibitors
GB201810669D0 (en) * 2018-06-28 2018-08-15 Stiftelsen Alzecure New compounds
CN118619944A (zh) * 2019-06-06 2024-09-10 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
JP7727627B2 (ja) 2019-12-04 2025-08-21 シーエイチディーアイ ファウンデーション，インコーポレーテッド Ａｔｍキナーゼ阻害剤及び組成物並びにそれらの使用の方法
KR20220153582A (ko) 2020-02-14 2022-11-18 솔크 인스티튜트 포 바이올로지칼 스터디즈 마크로시클릭 ulk1/2 억제제
KR20220153581A (ko) * 2020-02-14 2022-11-18 솔크 인스티튜트 포 바이올로지칼 스터디즈 Ulk1/2 의 억제제 및 이의 사용 방법
CN119841806A (zh) * 2023-10-16 2025-04-18 中国医学科学院药物研究所 多取代的喹唑啉类化合物及其制备方法、用途和药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100774855B1 (ko) * 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체
EA013811B1 (ru) * 2002-11-21 2010-08-30 Новартис Вэксинес Энд Дайэгностикс, Инк. 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
WO2005000404A2 (en) * 2003-05-29 2005-01-06 Synta Pharmaceuticals, Corp. Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
JP4906715B2 (ja) * 2004-05-08 2012-03-28 ニューロジェン・コーポレーション ４，５−ジ置換−２−アリールピリミジン類
US7851466B2 (en) * 2004-11-19 2010-12-14 Synta Pharmaceuticals Corp. Pyrimidine compounds and uses thereof
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds

Also Published As

Publication number Publication date
JP2010523639A (ja) 2010-07-15
BRPI0810641A2 (pt) 2019-09-24
EP2150546A2 (en) 2010-02-10
US20100130496A1 (en) 2010-05-27
EP2150546B1 (en) 2011-01-19
DE602008004650D1 (de) 2011-03-03
CN101765597A (zh) 2010-06-30
AU2008237721A1 (en) 2008-10-23
CA2683624A1 (en) 2008-10-23
KR20100016433A (ko) 2010-02-12
IL201365A0 (en) 2010-05-31
WO2008125839A3 (en) 2008-12-24
ATE496045T1 (de) 2011-02-15
WO2008125839A2 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
MX2009010886A (es) Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa.
MX2009010881A (es) Compuestos farmaceuticos.
GB0423653D0 (en) Pharmaceutical compounds
MX2008013578A (es) Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
MX2009010884A (es) 2-morfolin-4-il-pirimidinas como inhibidores de fosfatidilinositol-3-cinasa (pi3k).
WO2009053715A8 (en) Thienopyrimidiene derivatives as pi3k inhibitors
PH12014501504A1 (en) THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES
ATE510841T1 (de) Thiazoliopyrimidine und ihre verwendung als hemmer der phosphatidylinositol-3 kinase
SG178591A1 (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
PH12012501693A1 (en) 4 - [cycloalkyloxy (hetero) arylamino] thieno [2,3 - d] pyrimidines having mnkl/mnk2 inhibiting activity for pharmaceutical compositions
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
MX2009010037A (es) Aminopirimidinas utiles como inhibidores de cinasas.
WO2011014795A3 (en) Compounds and compositions as syk kinase inhibitors
MX2010003668A (es) Derivados de purina sustituidas con primidina.
PH12013501594A1 (en) Substituted indazole derivatives active as kinase inhibitors
PH12013500648A1 (en) Quinazolin-4 (3h) -one derivatives used as pi3 kinase inhibitors
MX2009011950A (es) Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr.
WO2010005558A3 (en) Pi3k isoform selective inhibitors
TN2009000444A1 (en) Combination therapy with a compound acting as a plateletadp receptor inhibitor
MX2009011811A (es) Aminopirimidinas utiles como inhibidores de cinasa.
MX2010006241A (es) Derivados de aminotriazol como agonistas de alx.
AU2009282962A8 (en) Compounds as kinase inhibitors
MX2012000166A (es) Compuestos de quinazolina que contienen fosforo y metodos de uso de los mismos.
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MX2012002327A (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal